鸡白细胞介素2基因的克隆、原核表达及功能研究

以RT-PCR法从鸡脾脏细胞中扩增出鸡白细胞介素2编码基因,通过双酶切、连接步骤克隆进原核表达载体pQE30及pGEX-4T-3,构建了鸡白细胞介素2基因的重组原核表达质粒pQE30-chIL-2及pGEX-chIL-2.重组质粒转化大肠杆菌JM109后经诱导表达,分别得到两种表达产物.以SDS-PAGE和Westernblot检测确认表达产物为带6组氨酸标签及GST蛋白的融合鸡白细胞介素2,分子量分别为16 kDa及39.5 kDa.表达蛋白与抗鸡白细胞介素2单抗均有良好的免疫结合性,进一步证实为鸡白细胞介素2.表达产物经过纯化复性后,具有明显促进鸡脾淋巴细胞增殖的作用.     

甲醛吸入对小鼠脾淋巴细胞分泌白细胞介素-2水平的影响

目的研究甲醛吸入对小鼠脾淋巴细胞分泌白细胞介素（IL）-2水平的影响。方法选用健康清洁级昆明种小鼠48只．随机分成4组（即阴性对照组．21．42．84mg／m3染毒组）．每组12只．用静式吸入染毒方式染毒12W处死后．测定小鼠脾淋巴细胞分泌IL-2的水平。结果甲醛吸入染毒组小鼠脾淋巴细胞分泌IL-2水平均随染毒剂量的升高而呈明显下降趋势（P〈0．05或,P〈0．01）。结论吸入甲醛可导致小鼠脾淋巴细胞分泌IL-2水平的下降。     

重组人VEGF165蛋白在毕赤酵母中高效表达与多克隆抗体的制备

构建pPIC9K-VEGF165分泌型载体,线性化后电击转化至GS115(his4)中,经最小葡萄糖培养基(MD平板)筛选出阳性表达菌株并进行聚合酶链式反应(PCR)验证.菌株发酵上清液经Sephadex G-25,Heparin Sepharose FF和Sephacryl S-100层析介质分离纯化,目的蛋白纯度达到95%,相对分子质量约为24ku.结果表明:重组人VEGF165蛋白能诱导人脐静脉内皮细胞(HUVEC)增殖,提高HUVEC细胞的活性;重组人VEGF165蛋白免疫小鼠,制备多克隆抗体,间接酶联免疫吸附测定法(ELISA)检测抗体效价达1:51 200.     

核桃楸树皮提取物抗肿瘤及免疫调节作用的研究

研究核桃楸树皮提取物(HT)的抗肿瘤及免疫调节作用.建立荷瘤小鼠模型,检测HT抑瘤率及对免疫器官、腹腔巨噬细胞吞噬功能、T淋巴细胞增殖、血清IL-2、TNF-α水平以及机体免疫功能的影响;建立小鼠免疫功能低下模型,检测HT对外周血细胞的影响.实验表明HT具有明显的抑瘤作用,高剂量组抑瘤率达54.6%,可显著提高荷瘤小鼠胸腺及脾脏系数、巨噬细胞吞噬功能、T淋巴细胞增殖I、L-2及TNF-α的表达以及延长游泳及耐缺氧时间,并能升高免疫抑制小鼠的白细胞(p<0.050~0.001).HT可有效抑制肿瘤增殖并调节机体的免疫功能.     

重组人脑利钠肽制备中内毒素的去除工艺

在重组人脑利钠肽(BNP)的分离纯化过程中去除内毒素,选用Chelating Sepharose FF亲和柱层析、Q Sepharose FF阴离子交换柱层析、Source 15反相柱层析、SP Sepharose FF阳离子交换柱层析组合的方法对BNP进行分离纯化。按照2015版药典中鲎试剂法检测各层析柱纯化阶段得到蛋白溶液中的内毒素含量;用HPLC方法检测各阶段所得蛋白的浓度和纯度。BNP制备过程中每一步层析在内毒素去除方面都有良好的效果,内毒素去除率超过90%;最终纯化所得BNP原液内毒素含量降至0.34 EU/0.5 mg,去除率高于99.99%,蛋白纯度高于98%。所设计的四步层析纯化分离方法在纯化重组人脑利钠肽的同时也能高效的去除蛋白溶液中内毒素,所得原液内毒素的含量远远低于国家药典对注射剂内毒素含量的最低限制,为重组人脑利钠肽的工业化生产奠定了基础。     

重组人脑利钠肽制备中内毒素去除工艺研究

[目的]在重组人脑利钠肽(BNP)的分离纯化过程中去除内毒素。[方法]选用Chelating Sepharose FF亲和柱层析、Q Sepharose FF阴离子交换柱层析、Source 15反相柱层析、SP Sepharose FF阳离子交换柱层析组合的方法对BNP进行分离纯化;按照2010版药典中鲎试剂法检测各层析柱纯化阶段得到蛋白溶液中的内毒素含量;并用HPLC方法检测各阶段所得蛋白的浓度和纯度。[结果]BNP制备过程中每一步层析在内毒素去除方面都有良好的效果,内毒素去除率超过90%;最终纯化所得BNP原液内毒素含量降至0.34EU/0.5mg,去除率高于99.99%,蛋白纯度高于98%;[结论]所设计的四步层析纯化分离方法在纯化重组人脑利钠肽的同时也能高效的去除蛋白溶液中内毒素,所得原液内毒素的含量远远低于国家药典对注射剂内毒素含量的最低限制,为重组脑利钠肽的工业化生产奠定了基础。     

幽门螺杆菌cag7-n基因克隆表达及其重组蛋白对BGC-823细胞生物学的影响

目的研究克隆幽门螺杆菌（Helicobacter pylori）cag7-n基因对BGC-823细胞增殖和IL-8分泌的影响.方法采用PCR技术从H.pylori基因组DNA中扩增cag7-n基因片段,构建重组质粒pET-28a-cag7-n,转化大肠杆菌BL21,经Western blot鉴定,纯化的蛋白作用于BGC-823细胞,用MTT法检测蛋白对细胞增殖的影响.结果成功克隆cag7-n基因,经镍柱纯化后可获得纯度为98%的重组蛋白.纯化蛋白浓度在100,150,200μg/mL时,培养时间延长,细胞的增殖受到抑制;在相同的培养时间,细胞的增殖程度随蛋白浓度的增加而降低.结论成功克隆了cag7-n基因,并在大肠杆菌BL21中表达,经过镍柱纯化后得到纯度较高的蛋白,纯化透析后的蛋白与BGC-823细胞共培养,可诱导细胞因子IL-8在mRNA水平上的表达及其对BGC-823细胞增殖的影响.     

重组肠激酶催化亚基在毕氏酵母中的高密度发酵、纯化及活性鉴定

应用RT-PCR和搭桥PCR技术,扩增肠激酶催化亚基的cDNA,测序正确后克隆至酵母分泌型表达质粒p9K中.将重组质粒p9K/EKLC转化至表达宿主pichia pastoris GS115,筛选得到高效表达重组牛肠激酶催化亚基工程菌.经甲醇诱导,目标蛋白肠激酶催化亚基(EKLC)表达并分泌至酵母培养基中.高密度发酵后,经超滤浓缩,采用SP Sepharose F.F一步纯化得到纯度达98%以上的重组目的蛋白,活性达到2.3 U/uL.上述结果表明,本实验成功获得了肠激酶催化亚基,它是一种能将融合蛋白中目标蛋白与载体蛋白裂解释放的有效工具酶.     

重组人截短型IL-6在大肠杆菌DH5α中的高效表达与纯化

为研究重组人截短型白细胞介素6(rhIL-6)工程菌高效表达的影响因素及纯化方法的优化.观察不同培养温度对重组人截短型IL-6工程菌生长密度和IL-6表达的影响;复性蛋白终浓度对复性效率的影响;细菌诱导培养后,经破菌-洗包-溶包初步纯化后,再经柱层析纯化IL-6.其结果为30℃培养后42℃诱导培养5h的IL-6表达效率最高,达32.8%;复性蛋白终浓度在0.5 g/L以下时,蛋白复性效率最佳,比活性为4.42×108 μmol/min*mg-1;进一步柱层析后,IL-6的纯度达96.5%,得率可达46.5%.最后得出培养和纯化工艺简便易行,可获得高纯度、高比活性的截短型rhIL-6的结论.     

血管抑素3A工程蛋白的柱复性与离子交换纯化

由大肠杆菌以包涵体形式表达的一种抗内皮细胞生长工程蛋白(A nti-ang iogen ic agent,简称3A)经变性,Sephacry l S-100 HR柱复性,SP Sepharose FF离子交换吸附纯化,SephadexG-25脱盐,获得复性率为53.47%,HPLC纯度为92.52%的3A活性蛋白。以猪髋动脉内皮细胞为受检细胞,表明纯化蛋白具有抑制内皮细胞生长的特性。     

绒白乳菇中提取的乳菇菌素-D免疫抑制作用的研究

研究从绒白乳菇菌中分离出的一种新型倍半萜类化合物-乳菇菌素D的免疫抑制作用及机制。运用体外培养法取BALB/C小鼠脾细胞,研究乳菇菌素D对静止脾细胞、Con A(刀豆蛋白A)和LPS(脂多糖)刺激后的脾细胞(含B淋巴细胞和T淋巴细胞)增殖的抑制作用;运用MTT法经酶标仪检测吸光度,并计算刺激指数(stimulating index,SI);体外培养小鼠脾细胞,运用ELISA检测法观察乳菇菌素D对脾脏中T淋巴细胞分泌IL-2的抑制作用。结果显示该化合物对静止的脾细胞无抑制作用;对Con A和LPS刺激后的脾细胞增殖有显著抑制作用(P0.05),最大浓度药物组刺激指数SI低至0.28;高浓度的乳菇菌素D对Con A刺激的小鼠脾细胞产生的IL-2,具有显著抑制作用(P0.05)。结果显示乳菇菌素D通过抑制抗原刺激后的T淋巴细胞和B淋巴细胞的增殖、抑制其分泌细胞因子,从而发挥免疫抑制作用。研究结果将为开发以乳菇菌素D为母体、经结构修饰、安全低毒的免疫抑制剂提供理论基础。     

IL-10修饰的树突状细胞的体外生物学效应研究

探讨lL-10修饰的树突状细胞（DC）对T细胞增殖和细胞毒性T细胞（CTL）胞毒活性的影响。采用乳酸脱氢酶法和ELISA法，分别测定细胞毒活性及T细胞凋亡。结果表明，IL-10对同种细胞刺激的增殖反应和特异性CTI．细胞毒活性有明显的抑制作用，修饰的DC诱导淋巴细胞增殖反应明显降低，而未修饰的DC诱导淋巴细胞增殖反应较强；IL-10和修饰的DC可诱导淋巴细胞凋亡．可见，稳定表达IL-10的DC，对T细胞增殖和对胞毒活性有明显的抑制作用，并可诱导T细胞凋亡。     

内皮细胞抑制素在毕节酵母中的表达与活性分析

采用PCR技术从人胎脑cDNA库中扩增了人内皮细胞抑制素基因。经DNA序列分析后将扩增的基因克隆至酵母载体pPICgK，获得的重组质粒pPIC9K-EDN转化毕节酵母GSll5，构建表达内皮细胞抑制素的酵母工程菌P.pastoris GSll5(pPIC9K-EDN)。SDS-PAGE分析结果显示：人内皮细胞抑制素在重组酵母GSll5(pPIC9K-EDN)中获得高效表达。用30L发酵罐构对建的工程菌进行高密度发酵，经甲醇诱导48h，生物量达到250OD，分泌量为150mg/L，发酵液经SP Streamline，SP Sepharose FF阳离子交换柱和SephamseHeparin Hi Trap柱纯化，产物纯度达到98％。纯化产物具有免疫活性并能抑制bFGF诱导的鸡胚绒毛尿囊膜血管生成。     

重组人组织型纤溶酶原激活剂缺失变体的工业化制备与性质研究

将含有人组织型纤溶酶原激活剂缺失变体(K2tPA)重组表达质粒的工程菌经10L种子罐培养及100L发酵,IPTG诱导表达,其表达量为占菌体总蛋白的20％,表达产物经体外变复性、TI—Sepharose亲和层析、SP-Sepharose离子交换层析,每100L发酵液得重组人组织型纤溶酶原激活剂缺失变体(K2tPA)纯品4g,纯度达95％以上,比活大于500000IU／mg,内毒素及热源含量、宿主蛋白残留量、宿主DNA残留量等均达到临床使用标准．其分子量(质谱测定)、氨基酸组成、N、C-端氨基酸序列分析等均与理论值相符．同时进行了等电点测定及肽图分析等性质研究．     

Functional maturation of two murine medullary-type CD8SP thymocytes

TCRαβCD4-CD8+ thymocytes are heterogeneity. They may undergo phenotypic and functional maturation within thymic medulla. Medullary-type CD8SP thymocytes were divided into seven subsets based on phenotypic analysis, and their precursor-progeny relationship along with the differential pathway was also delineated. To further testify the validity of the maturation pathway, we purified 6C10-CD69+ cells representing the early stage and 6C10-Qa-2+ cells representing the later stage among medullary-type CD8SP thymocytes and compared their functional maturation levels. CD8+ T cells of spleen were used as the control. It is shown that there is no obvious difference of proliferation ability among these three subsets; however, intracytoplasmic cytokine assay shows that there is a hier archy of IFN-γ and TNFα secretion among these subsets, strikingly comparable to their phenotypic status among medullary type CD8SP thymocytes. The bioassays of IL-2 and IFN-γ in culture supernatant give the similar results.     

The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3

CD2 (known also as T11 (ref. 1), LFA-2 (ref. 2) and the erythrocyte rosette receptor (ref. 3] is a functionally important T lymphocyte surface glycoprotein of relative molecular mass 50,000 to 58,000 (Mr 50-58 K) which appears early in thymocyte ontogeny and is present on all mature T cells. Monoclonal antibodies to CD2 inhibit cytotoxic T-lymphocyte (CTL)-mediated killing by binding to the T lymphocyte and blocking adhesion to the target cell. Such antibodies also inhibit T helper cell responses including antigen-stimulated proliferation, interleukin-2 (IL-2) secretion, and IL-2 receptor expression. Certain combinations of monoclonal antibodies to CD2 epitopes trigger proliferation of peripheral blood T lymphocytes, cytotoxic effector function and expression of IL-2 receptors by thymocytes, resulting in thymocyte proliferation in the presence of exogenous IL-2 (ref. 11). These findings suggest that CD2 can function in signalling as well as being an adhesion molecule. To understand the role of CD2 in T-cell adhesion and activation, it is essential to define its natural ligand. Our previous observation that purified CD2 inhibits rosetting of T lymphocytes with sheep erythrocytes and can be absorbed by sheep erythrocytes suggested it also might bind with detectable affinity to human cells. We now report that CD2 binds to a cell-surface antigen known as lymphocyte function-associated antigen-3 (LFA-3) with high affinity, and can mediate adhesion of lymphoid cells via interaction with LFA-3.     

人纤溶酶原Kringle5基因的克隆、表达及产物纯化和性质鉴定

根据人纤溶酶原的cDNA序列,利用PCR技术获得人纤溶酶原kringle5结构域的基因,并将其克隆至表达质粒pET25b( )中。重组载体pET25b（ ）/kringle5转化至大肠杆菌BL21（DE3）中,经IPTG诱导表达,在12kD处可见明显的表达条带,表达产物大部分以无活性的包涵体形式存在。包涵体经过体外变复性,SP-SepharoseFF离子交换柱一步纯化,15%SDS-PAGE鉴定考染一条带,纯度达95%以上。所得到的目标蛋白明显的抑制bFGF诱导的牛毛细血管内皮细胞增生。     

A new immunomodulating compound (AS-101) with potential therapeutic application

There has been interest in the potential of synthetic compounds to modify immune responses by imitation of cytokine action. Direct administration of interleukin 2 (IL-2) in conjunction with adoptive transfer of lymphokine activated killer cells has been used in the treatment of cancer, but there are toxic effects resulting from the high doses of IL-2 required. We have developed a new synthetic compound, ammonium tri-chloro(dioxoethylene-O,O'-)tellurate (AS-101), which has immunomodulating properties and minimal toxicity. The effects of AS-101 on the activation and function of immunocompetent cells have been assessed. We have found that AS-101 induces proliferation and IL-2 production by human lymphocytes in vitro, and enhances the production of IL-2 and colony-stimulating factor by mouse spleen cells. Splenocytes of BALB/c mice injected with AS-101 increased production of IL-2 and CSF in vitro in the presence of mitogen. Mononuclear cells of normal donors acquired responsiveness to recombinant IL-2 and bound monoclonal antibody to IL-2 receptor after incubation with AS-101. Splenocytes of mice treated in vivo with AS-101 expressed high levels of IL-2 receptor. The stimulation of lymphocytes by AS-101 apparently involves an increase in intracellular free calcium. AS-101 administered systemically to mice mediated antitumour effects which could be attributable to its immunomodulatory properties. In addition, AS-101 could directly enhance the ratio of OKT4 to OKT8-positive cells in cultured mononuclear cells from AIDS (acquired immune deficiency syndrome) patients. These results indicate that AS-101 is potentially useful in the treatment of clinical conditions involving immunosuppression.